Company news

XTL Biopharmaceuticals Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies

April 29, 2026

XTL Biopharmaceuticals Announces ADS Ratio Change

March 20, 2026

XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing

February 27, 2026

XTL Update on Recent Developments

January 29, 2026

XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders’ Equity Deficiency

January 23, 2026

XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership

January 13, 2026

XTL Biopharmaceuticals Acquires 85% of Beyond Air’s Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership

January 13, 2026

XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

December 24, 2025

XTL Names Mr. Noam Band as its New Chief Executive Officer

April 7, 2025

Decks

The 5 newest of 9 decks. Every deck is listed under its year.